Materiality
72
Source
External coverage
Decided
2026-06-17
J&J's CEO said the company has no plans to enter obesity drugs and will stay focused on areas like cancer, a modest negative for J&J's obesity-optionality narrative and a modest positive for incumbent obesity leaders such as Eli Lilly via reduced future competitive pressure.

